NEW YORK (GenomeWeb) – Life science reagents company Abcam said today that it has entered an agreement to acquire antibody firm AxioMx.

The company will purchase AxioMx for $20 million upfront followed by additional performance-based payments totaling up to $25 million, which will be made over five years and will be based upon successful completion of commercial and technical milestones.

Abcam said that it plans to use AxioMx's technology to develop highly validated recombinant antibodies to add to its existing catalogue.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.